rb 90740 has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, GE; Cole, S; Haigh, A; Jenner, T; Naylor, MA; Robertson, N; Siemann, D; Stephens, MA; Stratford, IJ | 1 |
| Adams, GE; Cole, S; Fielden, EM; Naylor, MA; Reeves, NJ; Stratford, IJ; Sutton, BM | 1 |
2 other study(ies) available for rb 90740 and Experimental Neoplasms
| Article | Year |
|---|---|
Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cricetinae; DNA Damage; Female; Male; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Pyrazines; Tumor Cells, Cultured | 1995 |
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H mice.
Topics: Animals; Antineoplastic Agents; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Pyrazines; Tissue Distribution | 1994 |